董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gary W. Pace | 男 | Director | 67 | 15.25万加拿大元 | 未持股 | 2015-09-14 |
| Tony F. Cruz | -- | Chief Executive Officer, Director | 62 | 96.61万加拿大元 | 未持股 | 2015-09-14 |
| Michael Ashton | 男 | Lead Director | 69 | 16.25万加拿大元 | 未持股 | 2015-09-14 |
| Christopher Henley | 男 | Director | 55 | 16.17万加拿大元 | 未持股 | 2015-09-14 |
| Paul Baeher | 男 | Director | 72 | 16.07万加拿大元 | 未持股 | 2015-09-14 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Tony F. Cruz | -- | Chief Executive Officer, Director | 62 | 96.61万加拿大元 | 未持股 | 2015-09-14 |
| Aleksandra Pastrak | -- | VP of Clinical Development,Medical Officer | 49 | 53.40万加拿大元 | 未持股 | 2015-09-14 |
| Nicole Rusaw George | -- | Chief Financial Officer | 42 | 48.87万加拿大元 | 未持股 | 2015-09-14 |
| Carl Damiani | -- | President,Chief Operating Officer | 43 | 31.98万加拿大元 | 未持股 | 2015-09-14 |
| Bruce Connop | -- | VP of Non-Clinical and Pharmaceutical Development | 46 | 28.72万加拿大元 | 未持股 | 2015-09-14 |
董事简历
中英对照 | 中文 | 英文- Gary W. Pace
-
Gary W. Pace. Pace博士自2002年以来一直担任该公司的董事。他目前是QRxPharma Ltd （ASX：QRX）的顾问和董事 ，是 ResMed （NYSE：RMD）和Transition Therapeutics Inc. （CDNX：TTH）的董事 。从 2002年到2007年，Pace博士就是 QRxPharma Pty Ltd的创始人，董事长兼首席执行官， 从1995年到2001年，他是 RTP Pharm的总裁兼首席执行官。从2000年到2002年，Pace博士是Waratah Pharmaceuticals Inc.董事长兼首席执行官，该公司是RTP Pharma的分拆公司。从1993年到1994年，他成立Transcend Therapeutics Inc.(原名Free Radical Sciences Inc.) 并担任总裁兼首席执行官，该公司是一个生物制药公司。从1989年到1993年，他是Clintec International, Inc.高级副总裁，该公司是一个巴克斯特/雀巢合资企业和临床营养产品的制造商。 Pace博士从University of New South Wales获得荣誉学士学位，从 麻省理工学院获得博士学位。
Gary W. Pace. Dr. Pace has served as a director of the Company since 2002. He is currently a consultant and Director of QRxPharma Ltd (ASX:QRX), and a director of ResMed (NYSE:RMD) and Transition Therapeutics Inc. (CDNX:TTH). From 2002 to 2007 Dr. Pace was Founder, Chairman and Chief Executive Officer of QRxPharma Pty Ltd and from 1995 to 2001 he was President and Chief Executive Officer of RTP Pharma and from 2000 to 2002 Dr. Pace was Chairman and Chief Executive Officer of Waratah Pharmaceuticals Inc., a spin-off company from RTP Pharma. From 1993 to 1994 he was the founding President and Chief Executive Officer of Transcend Therapeutics Inc. (formerly Free Radical Sciences Inc.), a biopharmaceutical company. From 1989 to 1993 he was Senior Vice president of Clintec International, Inc., a Baxter/Nestle joint venture and manufacturer of clinical nutritional products. Dr. Pace holds a B.S. with honors from the University of New South Wales and a Ph.D. from MIT. - Gary W. Pace. Pace博士自2002年以来一直担任该公司的董事。他目前是QRxPharma Ltd （ASX：QRX）的顾问和董事 ，是 ResMed （NYSE：RMD）和Transition Therapeutics Inc. （CDNX：TTH）的董事 。从 2002年到2007年，Pace博士就是 QRxPharma Pty Ltd的创始人，董事长兼首席执行官， 从1995年到2001年，他是 RTP Pharm的总裁兼首席执行官。从2000年到2002年，Pace博士是Waratah Pharmaceuticals Inc.董事长兼首席执行官，该公司是RTP Pharma的分拆公司。从1993年到1994年，他成立Transcend Therapeutics Inc.(原名Free Radical Sciences Inc.) 并担任总裁兼首席执行官，该公司是一个生物制药公司。从1989年到1993年，他是Clintec International, Inc.高级副总裁，该公司是一个巴克斯特/雀巢合资企业和临床营养产品的制造商。 Pace博士从University of New South Wales获得荣誉学士学位，从 麻省理工学院获得博士学位。
- Gary W. Pace. Dr. Pace has served as a director of the Company since 2002. He is currently a consultant and Director of QRxPharma Ltd (ASX:QRX), and a director of ResMed (NYSE:RMD) and Transition Therapeutics Inc. (CDNX:TTH). From 2002 to 2007 Dr. Pace was Founder, Chairman and Chief Executive Officer of QRxPharma Pty Ltd and from 1995 to 2001 he was President and Chief Executive Officer of RTP Pharma and from 2000 to 2002 Dr. Pace was Chairman and Chief Executive Officer of Waratah Pharmaceuticals Inc., a spin-off company from RTP Pharma. From 1993 to 1994 he was the founding President and Chief Executive Officer of Transcend Therapeutics Inc. (formerly Free Radical Sciences Inc.), a biopharmaceutical company. From 1989 to 1993 he was Senior Vice president of Clintec International, Inc., a Baxter/Nestle joint venture and manufacturer of clinical nutritional products. Dr. Pace holds a B.S. with honors from the University of New South Wales and a Ph.D. from MIT.
- Tony F. Cruz
-
Tony F. Cruz博士，该公司的首席执行官。
Tony F. Cruz,Chief Executive Officer of the Corporation. - Tony F. Cruz博士，该公司的首席执行官。
- Tony F. Cruz,Chief Executive Officer of the Corporation.
- Michael Ashton
-
自2006年3月以来，Michael Ashton担任医药行业的独立顾问，此前曾担任斯凯制药公共有限公司（Skye Pharma PLC）--一家英国的药物递送公司的首席执行官。
Michael Ashton,In June, 2015 Mr. Ashton retired as the Chief Executive Officer of Puricore PLC. Mr. Ashton has been an independent consultant to the pharmaceutical industry since March 2006. Prior thereto, he was the Chief Executive Officer of SkyePharma PLC. He has over 30 years of experience in the pharmaceutical industry having worked for Merck, Pfizer, Purepac and Faulding, where Mr. Ashton was Chairman, President and CEO. Mr. Ashton is a member of the Board of Directors of Hikma Pharmaceuticals PLC. Mr. Ashton has a Bachelor of Pharmacy degree from Sydney University and his MBA degree from Rutgers University, New Jersey. - 自2006年3月以来，Michael Ashton担任医药行业的独立顾问，此前曾担任斯凯制药公共有限公司（Skye Pharma PLC）--一家英国的药物递送公司的首席执行官。
- Michael Ashton,In June, 2015 Mr. Ashton retired as the Chief Executive Officer of Puricore PLC. Mr. Ashton has been an independent consultant to the pharmaceutical industry since March 2006. Prior thereto, he was the Chief Executive Officer of SkyePharma PLC. He has over 30 years of experience in the pharmaceutical industry having worked for Merck, Pfizer, Purepac and Faulding, where Mr. Ashton was Chairman, President and CEO. Mr. Ashton is a member of the Board of Directors of Hikma Pharmaceuticals PLC. Mr. Ashton has a Bachelor of Pharmacy degree from Sydney University and his MBA degree from Rutgers University, New Jersey.
- Christopher Henley
-
Christopher Henley，亨利资本公司（Henley Capital Corporation）董事长，是免税市场代理商和投资组合经理。
Christopher Henley,has a B.A. from Memorial University and an MBA from Dalhousie University. He has completed the Institute of Corporate Directors Education Program at the Rotman School of Management, University of Toronto and holds the professional designation ICD.D. He is currently founder and President of Henley Capital Corporation, an exempt market dealer and portfolio manager.Mr. Henley has been an investment banker for over 25 years and previously was the head of investment banking in Toronto at what was then Canada’s largest independent employee-owned investment dealer where he also ran the firm’s High Technology and Communications practice. Mr. Henley is a former board member of the Exempt Market Dealers Association of Canada, a former director and Chair of the Toronto Port Authority, a former member of the Board and Audit Committee of Ontario Transportation Capital Corporation, a Government of Ontario Crown Corporation that, through a public partnership, developed Highway 407 in Toronto, Ontario, the first all-electronic toll highway in the world. Mr. Henley is also a founding member of the National Angel Organization in Canada and the Ministers’ Technology Advisory Group “MTAG” for the Province of Ontario. He is also a former Chair of the MTAG Task Force on Access to Capital, a former member of the Advisory Board, Faculty of Business Administration, Memorial University of Newfoundland and is an active member of the Institute of Corporate Directors. Mr. Henley is currently Chair of West Park Healthcare Centre, a member of the Governance Committee of the Ontario Cancer Research Ethics Board, and is actively involved in many philanthropic organizations including acting as Chair of the Board of the McMichael Canadian Art Foundation. - Christopher Henley，亨利资本公司（Henley Capital Corporation）董事长，是免税市场代理商和投资组合经理。
- Christopher Henley,has a B.A. from Memorial University and an MBA from Dalhousie University. He has completed the Institute of Corporate Directors Education Program at the Rotman School of Management, University of Toronto and holds the professional designation ICD.D. He is currently founder and President of Henley Capital Corporation, an exempt market dealer and portfolio manager.Mr. Henley has been an investment banker for over 25 years and previously was the head of investment banking in Toronto at what was then Canada’s largest independent employee-owned investment dealer where he also ran the firm’s High Technology and Communications practice. Mr. Henley is a former board member of the Exempt Market Dealers Association of Canada, a former director and Chair of the Toronto Port Authority, a former member of the Board and Audit Committee of Ontario Transportation Capital Corporation, a Government of Ontario Crown Corporation that, through a public partnership, developed Highway 407 in Toronto, Ontario, the first all-electronic toll highway in the world. Mr. Henley is also a founding member of the National Angel Organization in Canada and the Ministers’ Technology Advisory Group “MTAG” for the Province of Ontario. He is also a former Chair of the MTAG Task Force on Access to Capital, a former member of the Advisory Board, Faculty of Business Administration, Memorial University of Newfoundland and is an active member of the Institute of Corporate Directors. Mr. Henley is currently Chair of West Park Healthcare Centre, a member of the Governance Committee of the Ontario Cancer Research Ethics Board, and is actively involved in many philanthropic organizations including acting as Chair of the Board of the McMichael Canadian Art Foundation.
- Paul Baeher
-
Paul Baeher是IBEX 技术公司（IBEX Technologies Inc.）--一家公开上市的生物技术公司的总裁，首席执行官以及董事长。
Paul Baeher,President,has a B.A. from the University of British Columbia. He is currently President, Chief Executive Officer and Chairman of IBEX Technologies Inc., a biotechnology company listed on the TSX under the symbol “IBT”. Previously, Mr. Baehr was an Executive Vice President at Sterling Winthrop and prior thereto a Senior Vice President at CIBA-GEIGY Pharmaceuticals, both of which are large pharmaceutical companies. In addition, Mr. Baehr currently sits on the board of directors of IBEX Technologies Inc., a public company. - Paul Baeher是IBEX 技术公司（IBEX Technologies Inc.）--一家公开上市的生物技术公司的总裁，首席执行官以及董事长。
- Paul Baeher,President,has a B.A. from the University of British Columbia. He is currently President, Chief Executive Officer and Chairman of IBEX Technologies Inc., a biotechnology company listed on the TSX under the symbol “IBT”. Previously, Mr. Baehr was an Executive Vice President at Sterling Winthrop and prior thereto a Senior Vice President at CIBA-GEIGY Pharmaceuticals, both of which are large pharmaceutical companies. In addition, Mr. Baehr currently sits on the board of directors of IBEX Technologies Inc., a public company.
高管简历
中英对照 | 中文 | 英文- Tony F. Cruz
Tony F. Cruz博士，该公司的首席执行官。
Tony F. Cruz,Chief Executive Officer of the Corporation.- Tony F. Cruz博士，该公司的首席执行官。
- Tony F. Cruz,Chief Executive Officer of the Corporation.
- Aleksandra Pastrak
自2011年9月以来，Aleksandra Pastrak博士担任临床开发和医疗部副总裁。此前自2007年7月，担任该公司的研究和医疗部副总裁；从2005年5月开始公司担任研究部副总裁。
Aleksandra Pastrak,VP of Clinical Development and Medical Officer since September 2011 prior thereto, VP Research and Medical Officer of the Corporation since July 2007 prior thereto, VP, Research of the Corporation since May 2005.- 自2011年9月以来，Aleksandra Pastrak博士担任临床开发和医疗部副总裁。此前自2007年7月，担任该公司的研究和医疗部副总裁；从2005年5月开始公司担任研究部副总裁。
- Aleksandra Pastrak,VP of Clinical Development and Medical Officer since September 2011 prior thereto, VP Research and Medical Officer of the Corporation since July 2007 prior thereto, VP, Research of the Corporation since May 2005.
- Nicole Rusaw George
自2011年12月以来，Nicole Rusaw George担任公司的首席财务官；此前，自2008年7月开始，是该公司的财务副总裁。自2005年6月，为公司的财务总监。
Nicole Rusaw George, Chief Financial Officer of the Corporation since December 2011; prior thereto, VP, Finance of the Corporation since July 2008 prior thereto, Director of Finance of the Corporation since June 2005.- 自2011年12月以来，Nicole Rusaw George担任公司的首席财务官；此前，自2008年7月开始，是该公司的财务副总裁。自2005年6月，为公司的财务总监。
- Nicole Rusaw George, Chief Financial Officer of the Corporation since December 2011; prior thereto, VP, Finance of the Corporation since July 2008 prior thereto, Director of Finance of the Corporation since June 2005.
- Carl Damiani
自2007年12月以来，Carl Damiani担任公司业务发展总监，此前，从2003年10月开始，他是公司的业务发展副总裁。
Carl Damiani,President and Chief Operating Officer of the Corporation since June 16 2015; prior thereto, Chief Operating Officer of the Corporation since July 11 2014; prior thereto, VP of Business Development of the Corporation since December 2007 prior thereto, Director of Business Development of the Corporation since October 2003.- 自2007年12月以来，Carl Damiani担任公司业务发展总监，此前，从2003年10月开始，他是公司的业务发展副总裁。
- Carl Damiani,President and Chief Operating Officer of the Corporation since June 16 2015; prior thereto, Chief Operating Officer of the Corporation since July 11 2014; prior thereto, VP of Business Development of the Corporation since December 2007 prior thereto, Director of Business Development of the Corporation since October 2003.
- Bruce Connop
自2012年7月以来，Bruce Connop担任公司非临床药物开发的高级主管，此前自2006年12月，为公司非临床药物开发的副总裁。
Bruce Connop,VP of Non-Clinical and Pharmaceutical Development of the Corporation since July 2012 prior thereto, Senior Director Non-Clinical Drug Development since December 2006.- 自2012年7月以来，Bruce Connop担任公司非临床药物开发的高级主管，此前自2006年12月，为公司非临床药物开发的副总裁。
- Bruce Connop,VP of Non-Clinical and Pharmaceutical Development of the Corporation since July 2012 prior thereto, Senior Director Non-Clinical Drug Development since December 2006.